DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) announced today an alliance with Merck under which it will provide its patented PhosphoScan® proteomics technology for biomarker discovery and its expertise in antibody development and validation to develop high specificity biomarker assays to help advance Merck’s targeted therapeutic programs for oncology.
